Efficacy of Neuroendoscopic Treatment for Septated Chronic Subdural Hematoma
Open Access
- 11 January 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12, 765109
- https://doi.org/10.3389/fneur.2021.765109
Abstract
Objective: Neuroendoscopic treatment is an alternative therapeutic strategy for the treatment of septate chronic subdural hematoma (sCSDH). However, the safety and efficacy of this strategy remain controversial. We compared the clinical outcomes of neuroendoscopic treatment with those of standard (large bone flap) craniotomy for sCSDH reported in our center. Furthermore, the safety and efficacy of the neuroendoscopic treatment procedure for sCSDH were evaluated. Methods: We retrospectively collected the clinical data of 43 patients (37 men and six women) with sCSDH who underwent either neuroendoscopic treatment or standard (large bone flap) craniotomy, such as sex, age, smoking, drinking, medical history, use of antiplatelet drugs, postoperative complications, sCSDH recurrence, length of hospital stay, and postoperative hospital stay. We recorded the surgical procedures and the neurological function recovery prior to surgery and 6 months following the surgical treatment. Results: The enrolled patients were categorized into neuroendoscopic treatment (n = 23) and standard (large bone flap) craniotomy (n = 20) groups. There were no differences in sex, age, smoking, drinking, medical history, antiplatelet drug use, postoperative complications, and sCSDH recurrence between the two groups (p > 0.05). However, the patients in neuroendoscopic treatment group had a shorter length of total hospital stay and postoperative hospital stay as compared with the standard craniotomy group (total hospital stay: 5.26 ± 1.89 vs. 8.15 ± 1.04 days, p < 0.001; postoperative hospital stay: 4.47 ± 1.95 vs. 7.96 ± 0.97 days, p < 0.001). The imaging and Modified Rankin Scale at the 6-month follow-up were satisfactory, and no sCSDH recurrence was reported in the two groups. Conclusions: The findings of this study indicate that neuroendoscopic treatment is safe and effective for sCSDH; it is minimally invasive and could be clinically utilized.This publication has 15 references indexed in Scilit:
- Subperiosteal vs Subdural Drain After Burr-Hole Drainage of Chronic Subdural Hematoma: A Randomized Clinical Trial (cSDH-Drain-Trial)Neurosurgery, 2019
- Which surgical procedure is effective for refractory chronic subdural hematoma? Analysis of our surgical procedures and literature reviewJournal of Clinical Neuroscience, 2018
- Pathophysiology of chronic subdural haematoma: inflammation, angiogenesis and implications for pharmacotherapyJournal of Neuroinflammation, 2017
- Craniotomy for Treatment of Chronic Subdural HematomaNeurosurgery Clinics of North America, 2017
- The minimally invasive endoscopic management of septated chronic subdural hematomas: surgical techniqueActa Neurochirurgica, 2014
- Twist-drill craniostomy with hollow screws for evacuation of chronic subdural hematomaJournal of Neurosurgery, 2014
- Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trialThe Lancet, 2009
- Brain herniation through an internal subdural membrane: a rare complication seen with chronic subdural hematomas in childrenJournal of Neurosurgery: Pediatrics, 2007
- Outcome of contemporary surgery for chronic subdural haematoma: evidence based reviewJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Twist-drill craniostomy for the treatment of chronic subdural hematoma.Neurosurgery Clinics of North America, 2000